+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07632079

Study of Hypofractionated Chemoradiotherapy Using Carboplatin and Paclitaxel for Locally Advanced Esophageal or Gastroesophageal Junction Cancer

Led by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Updated on 2026-06-08

60

Participants Needed

7

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating hypofractionated definitive chemoradiotherapy as a treatment for patients with locally advanced esophageal or gastroesophageal junction GEJ cancer. This study aims to determine if delivering a shorter, more intense course of radiation combined with chemotherapy is feasible and safe, with a focus on understanding treatment-related toxicity, especially radiation-induced lymphopenia. Participants will receive 20 fractions of 2.4 Gy radiation alongside six cycles of carboplatin and paclitaxel chemotherapy over four weeks. This approach is compared to the usual treatment of 28 fractions over 5.5 weeks with the same chemotherapy regimen. After treatment, participants will undergo follow-up according to standard care practices. Throughout the study, researchers will monitor how many patients complete the full course of radiotherapy and chemotherapy. They will also assess the incidence and severity of lymphopenia and other acute toxicities at multiple time points during and after treatment. This includes blood tests and clinical evaluations up to three months post-treatment to ensure safety and gather comprehensive outcome data.

CONDITIONS

Brief Title

Hypofractionated Definitive Chemoradiotherapy for Oesophageal Cancer

Research Team

I

Iris Agterberg

D

Dr. P.S.N. van Rossum

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here